nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—HTR2B—Sorafenib—thyroid cancer	0.256	0.424	CbGbCtD
Raloxifene—CYP2B6—Sorafenib—thyroid cancer	0.103	0.171	CbGbCtD
Raloxifene—CYP2C8—Sorafenib—thyroid cancer	0.0783	0.13	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—thyroid cancer	0.0628	0.104	CbGbCtD
Raloxifene—CYP3A4—Vandetanib—thyroid cancer	0.0527	0.0872	CbGbCtD
Raloxifene—CYP3A4—Sorafenib—thyroid cancer	0.0318	0.0526	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—thyroid cancer	0.0193	0.0319	CbGbCtD
Raloxifene—Cholelithiasis—Vandetanib—thyroid cancer	0.00745	0.0273	CcSEcCtD
Raloxifene—Laryngitis—Vandetanib—thyroid cancer	0.00642	0.0236	CcSEcCtD
Raloxifene—Embolism venous—Sorafenib—thyroid cancer	0.00619	0.0227	CcSEcCtD
Raloxifene—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00531	0.0195	CcSEcCtD
Raloxifene—Embolism—Sorafenib—thyroid cancer	0.00487	0.0179	CcSEcCtD
Raloxifene—Cystitis noninfective—Vandetanib—thyroid cancer	0.00452	0.0166	CcSEcCtD
Raloxifene—Cystitis—Vandetanib—thyroid cancer	0.00447	0.0164	CcSEcCtD
Raloxifene—Bladder pain—Vandetanib—thyroid cancer	0.00419	0.0154	CcSEcCtD
Raloxifene—Venous thromboembolism—Epirubicin—thyroid cancer	0.00393	0.0144	CcSEcCtD
Raloxifene—Gastroenteritis—Vandetanib—thyroid cancer	0.00379	0.0139	CcSEcCtD
Raloxifene—Neoplasm malignant—Sorafenib—thyroid cancer	0.00366	0.0134	CcSEcCtD
Raloxifene—Venous thromboembolism—Doxorubicin—thyroid cancer	0.00363	0.0133	CcSEcCtD
Raloxifene—Blood pressure increased—Sorafenib—thyroid cancer	0.00312	0.0115	CcSEcCtD
Raloxifene—Influenza—Vandetanib—thyroid cancer	0.0029	0.0107	CcSEcCtD
Raloxifene—Bronchitis—Vandetanib—thyroid cancer	0.00279	0.0103	CcSEcCtD
Raloxifene—Pneumonia—Vandetanib—thyroid cancer	0.00261	0.00956	CcSEcCtD
Raloxifene—Depression—Vandetanib—thyroid cancer	0.00258	0.00948	CcSEcCtD
Raloxifene—Conjunctivitis—Vandetanib—thyroid cancer	0.00252	0.00924	CcSEcCtD
Raloxifene—Urinary tract infection—Vandetanib—thyroid cancer	0.00252	0.00924	CcSEcCtD
Raloxifene—Leukorrhea—Epirubicin—thyroid cancer	0.00246	0.00904	CcSEcCtD
Raloxifene—Sinusitis—Vandetanib—thyroid cancer	0.00243	0.00892	CcSEcCtD
Raloxifene—Urinary tract disorder—Vandetanib—thyroid cancer	0.0023	0.00843	CcSEcCtD
Raloxifene—Embolism venous—Epirubicin—thyroid cancer	0.00229	0.0084	CcSEcCtD
Raloxifene—Urethral disorder—Vandetanib—thyroid cancer	0.00228	0.00837	CcSEcCtD
Raloxifene—Leukorrhea—Doxorubicin—thyroid cancer	0.00228	0.00836	CcSEcCtD
Raloxifene—Cardiac disorder—Vandetanib—thyroid cancer	0.00216	0.00792	CcSEcCtD
Raloxifene—Embolism venous—Doxorubicin—thyroid cancer	0.00212	0.00777	CcSEcCtD
Raloxifene—Angiopathy—Vandetanib—thyroid cancer	0.00211	0.00774	CcSEcCtD
Raloxifene—Breast disorder—Sorafenib—thyroid cancer	0.00205	0.00752	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00204	0.0075	CcSEcCtD
Raloxifene—ESR2—neck—thyroid cancer	0.00197	0.107	CbGeAlD
Raloxifene—Muscle spasms—Vandetanib—thyroid cancer	0.00195	0.00714	CcSEcCtD
Raloxifene—Vaginal discharge—Epirubicin—thyroid cancer	0.0019	0.00697	CcSEcCtD
Raloxifene—Embolism—Epirubicin—thyroid cancer	0.0018	0.0066	CcSEcCtD
Raloxifene—Loss of consciousness—Vandetanib—thyroid cancer	0.00178	0.00653	CcSEcCtD
Raloxifene—Cough—Vandetanib—thyroid cancer	0.00177	0.00648	CcSEcCtD
Raloxifene—Pneumonia—Sorafenib—thyroid cancer	0.00176	0.00645	CcSEcCtD
Raloxifene—Vaginal discharge—Doxorubicin—thyroid cancer	0.00176	0.00645	CcSEcCtD
Raloxifene—Arthralgia—Vandetanib—thyroid cancer	0.00172	0.00633	CcSEcCtD
Raloxifene—Chest pain—Vandetanib—thyroid cancer	0.00172	0.00633	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00171	0.00628	CcSEcCtD
Raloxifene—Embolism—Doxorubicin—thyroid cancer	0.00166	0.00611	CcSEcCtD
Raloxifene—Neuralgia—Epirubicin—thyroid cancer	0.00166	0.0061	CcSEcCtD
Raloxifene—Infection—Vandetanib—thyroid cancer	0.00164	0.00603	CcSEcCtD
Raloxifene—Nervous system disorder—Vandetanib—thyroid cancer	0.00162	0.00595	CcSEcCtD
Raloxifene—Thrombocytopenia—Vandetanib—thyroid cancer	0.00162	0.00594	CcSEcCtD
Raloxifene—Skin disorder—Vandetanib—thyroid cancer	0.0016	0.00589	CcSEcCtD
Raloxifene—Laryngitis—Epirubicin—thyroid cancer	0.0016	0.00588	CcSEcCtD
Raloxifene—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.00156	0.00573	CcSEcCtD
Raloxifene—Urinary tract disorder—Sorafenib—thyroid cancer	0.00155	0.00569	CcSEcCtD
Raloxifene—Connective tissue disorder—Sorafenib—thyroid cancer	0.00154	0.00566	CcSEcCtD
Raloxifene—Urethral disorder—Sorafenib—thyroid cancer	0.00154	0.00564	CcSEcCtD
Raloxifene—Neuralgia—Doxorubicin—thyroid cancer	0.00154	0.00564	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.0015	0.00553	CcSEcCtD
Raloxifene—Insomnia—Vandetanib—thyroid cancer	0.00149	0.00549	CcSEcCtD
Raloxifene—Laryngitis—Doxorubicin—thyroid cancer	0.00148	0.00544	CcSEcCtD
Raloxifene—Cardiac disorder—Sorafenib—thyroid cancer	0.00146	0.00534	CcSEcCtD
Raloxifene—Flushing—Sorafenib—thyroid cancer	0.00146	0.00534	CcSEcCtD
Raloxifene—Dyspepsia—Vandetanib—thyroid cancer	0.00145	0.00534	CcSEcCtD
Raloxifene—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.00144	0.0053	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00143	0.00524	CcSEcCtD
Raloxifene—Angiopathy—Sorafenib—thyroid cancer	0.00142	0.00522	CcSEcCtD
Raloxifene—Pain—Vandetanib—thyroid cancer	0.00141	0.00519	CcSEcCtD
Raloxifene—Neoplasm malignant—Epirubicin—thyroid cancer	0.00135	0.00496	CcSEcCtD
Raloxifene—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00135	0.00496	CcSEcCtD
Raloxifene—ESR1—neck—thyroid cancer	0.00135	0.0731	CbGeAlD
Raloxifene—Breast pain—Epirubicin—thyroid cancer	0.00132	0.00486	CcSEcCtD
Raloxifene—Vasodilation—Epirubicin—thyroid cancer	0.00131	0.00482	CcSEcCtD
Raloxifene—Vasodilation procedure—Epirubicin—thyroid cancer	0.00131	0.00482	CcSEcCtD
Raloxifene—Muscle spasms—Sorafenib—thyroid cancer	0.00131	0.00482	CcSEcCtD
Raloxifene—Abdominal pain—Vandetanib—thyroid cancer	0.00131	0.00479	CcSEcCtD
Raloxifene—Body temperature increased—Vandetanib—thyroid cancer	0.00131	0.00479	CcSEcCtD
Raloxifene—Cough increased—Epirubicin—thyroid cancer	0.00126	0.00463	CcSEcCtD
Raloxifene—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00125	0.00459	CcSEcCtD
Raloxifene—Syncope—Sorafenib—thyroid cancer	0.00122	0.0045	CcSEcCtD
Raloxifene—Breast pain—Doxorubicin—thyroid cancer	0.00122	0.00449	CcSEcCtD
Raloxifene—Vasodilation—Doxorubicin—thyroid cancer	0.00122	0.00446	CcSEcCtD
Raloxifene—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00122	0.00446	CcSEcCtD
Raloxifene—Loss of consciousness—Sorafenib—thyroid cancer	0.0012	0.00441	CcSEcCtD
Raloxifene—Cough—Sorafenib—thyroid cancer	0.00119	0.00437	CcSEcCtD
Raloxifene—SIGMAR1—saliva-secreting gland—thyroid cancer	0.00119	0.0645	CbGeAlD
Raloxifene—HTR6—head—thyroid cancer	0.00118	0.0642	CbGeAlD
Raloxifene—Cough increased—Doxorubicin—thyroid cancer	0.00117	0.00428	CcSEcCtD
Raloxifene—Myalgia—Sorafenib—thyroid cancer	0.00116	0.00427	CcSEcCtD
Raloxifene—Arthralgia—Sorafenib—thyroid cancer	0.00116	0.00427	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00115	0.00424	CcSEcCtD
Raloxifene—Pulmonary embolism—Epirubicin—thyroid cancer	0.00115	0.00424	CcSEcCtD
Raloxifene—Vaginal inflammation—Epirubicin—thyroid cancer	0.00115	0.00424	CcSEcCtD
Raloxifene—AOX1—trachea—thyroid cancer	0.00114	0.0618	CbGeAlD
Raloxifene—Diarrhoea—Vandetanib—thyroid cancer	0.00113	0.00415	CcSEcCtD
Raloxifene—Cystitis noninfective—Epirubicin—thyroid cancer	0.00113	0.00414	CcSEcCtD
Raloxifene—Cystitis—Epirubicin—thyroid cancer	0.00111	0.00409	CcSEcCtD
Raloxifene—Infection—Sorafenib—thyroid cancer	0.00111	0.00406	CcSEcCtD
Raloxifene—Shock—Sorafenib—thyroid cancer	0.0011	0.00403	CcSEcCtD
Raloxifene—Nervous system disorder—Sorafenib—thyroid cancer	0.00109	0.00401	CcSEcCtD
Raloxifene—Dizziness—Vandetanib—thyroid cancer	0.00109	0.00401	CcSEcCtD
Raloxifene—Thrombocytopenia—Sorafenib—thyroid cancer	0.00109	0.00401	CcSEcCtD
Raloxifene—Vaginal infection—Epirubicin—thyroid cancer	0.00109	0.004	CcSEcCtD
Raloxifene—Skin disorder—Sorafenib—thyroid cancer	0.00108	0.00397	CcSEcCtD
Raloxifene—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00107	0.00392	CcSEcCtD
Raloxifene—Vaginal inflammation—Doxorubicin—thyroid cancer	0.00107	0.00392	CcSEcCtD
Raloxifene—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00106	0.00389	CcSEcCtD
Raloxifene—Vomiting—Vandetanib—thyroid cancer	0.00105	0.00386	CcSEcCtD
Raloxifene—Bladder pain—Epirubicin—thyroid cancer	0.00104	0.00383	CcSEcCtD
Raloxifene—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00104	0.00383	CcSEcCtD
Raloxifene—Rash—Vandetanib—thyroid cancer	0.00104	0.00382	CcSEcCtD
Raloxifene—Dermatitis—Vandetanib—thyroid cancer	0.00104	0.00382	CcSEcCtD
Raloxifene—Headache—Vandetanib—thyroid cancer	0.00103	0.0038	CcSEcCtD
Raloxifene—Cystitis—Doxorubicin—thyroid cancer	0.00103	0.00379	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00102	0.00373	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—thyroid cancer	0.00101	0.0037	CcSEcCtD
Raloxifene—Nausea—Vandetanib—thyroid cancer	0.000981	0.0036	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000981	0.0036	CcSEcCtD
Raloxifene—Dyspepsia—Sorafenib—thyroid cancer	0.000981	0.0036	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—thyroid cancer	0.000966	0.00355	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—thyroid cancer	0.000963	0.00354	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000962	0.00353	CcSEcCtD
Raloxifene—Pain—Sorafenib—thyroid cancer	0.000953	0.0035	CcSEcCtD
Raloxifene—ESR2—thyroid gland—thyroid cancer	0.000937	0.0508	CbGeAlD
Raloxifene—SIGMAR1—trachea—thyroid cancer	0.000918	0.0498	CbGeAlD
Raloxifene—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000911	0.00335	CcSEcCtD
Raloxifene—AOX1—thyroid gland—thyroid cancer	0.000902	0.0489	CbGeAlD
Raloxifene—Hot flush—Epirubicin—thyroid cancer	0.000896	0.00329	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000891	0.00327	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—thyroid cancer	0.000888	0.00326	CcSEcCtD
Raloxifene—Abdominal pain—Sorafenib—thyroid cancer	0.000881	0.00323	CcSEcCtD
Raloxifene—Body temperature increased—Sorafenib—thyroid cancer	0.000881	0.00323	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000855	0.00314	CcSEcCtD
Raloxifene—ESR2—head—thyroid cancer	0.000832	0.0451	CbGeAlD
Raloxifene—Hot flush—Doxorubicin—thyroid cancer	0.000829	0.00304	CcSEcCtD
Raloxifene—Migraine—Epirubicin—thyroid cancer	0.000825	0.00303	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000822	0.00302	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000791	0.0029	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—thyroid cancer	0.000763	0.0028	CcSEcCtD
Raloxifene—Diarrhoea—Sorafenib—thyroid cancer	0.000762	0.0028	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—thyroid cancer	0.000757	0.00278	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000754	0.00277	CcSEcCtD
Raloxifene—CYP19A1—thyroid gland—thyroid cancer	0.000739	0.04	CbGeAlD
Raloxifene—Dizziness—Sorafenib—thyroid cancer	0.000737	0.00271	CcSEcCtD
Raloxifene—SIGMAR1—thyroid gland—thyroid cancer	0.000726	0.0394	CbGeAlD
Raloxifene—HTR2B—thyroid gland—thyroid cancer	0.000725	0.0393	CbGeAlD
Raloxifene—Influenza—Epirubicin—thyroid cancer	0.000724	0.00266	CcSEcCtD
Raloxifene—Vomiting—Sorafenib—thyroid cancer	0.000708	0.0026	CcSEcCtD
Raloxifene—Rash—Sorafenib—thyroid cancer	0.000703	0.00258	CcSEcCtD
Raloxifene—Dermatitis—Sorafenib—thyroid cancer	0.000702	0.00258	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—thyroid cancer	0.000701	0.00257	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000698	0.00256	CcSEcCtD
Raloxifene—Headache—Sorafenib—thyroid cancer	0.000698	0.00256	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—thyroid cancer	0.000696	0.00256	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—thyroid cancer	0.00067	0.00246	CcSEcCtD
Raloxifene—Nausea—Sorafenib—thyroid cancer	0.000662	0.00243	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—thyroid cancer	0.000659	0.00242	CcSEcCtD
Raloxifene—CYP19A1—head—thyroid cancer	0.000655	0.0355	CbGeAlD
Raloxifene—Pneumonia—Epirubicin—thyroid cancer	0.000649	0.00238	CcSEcCtD
Raloxifene—Bronchitis—Doxorubicin—thyroid cancer	0.000644	0.00237	CcSEcCtD
Raloxifene—HTR2B—head—thyroid cancer	0.000643	0.0348	CbGeAlD
Raloxifene—ESR1—thyroid gland—thyroid cancer	0.000642	0.0348	CbGeAlD
Raloxifene—Urinary tract infection—Epirubicin—thyroid cancer	0.000628	0.0023	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—thyroid cancer	0.000628	0.0023	CcSEcCtD
Raloxifene—Sweating—Epirubicin—thyroid cancer	0.000619	0.00227	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—thyroid cancer	0.00061	0.00224	CcSEcCtD
Raloxifene—Sinusitis—Epirubicin—thyroid cancer	0.000606	0.00222	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—thyroid cancer	0.000601	0.00221	CcSEcCtD
Raloxifene—ESR2—lymph node—thyroid cancer	0.000582	0.0316	CbGeAlD
Raloxifene—Rhinitis—Epirubicin—thyroid cancer	0.000581	0.00213	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—thyroid cancer	0.000581	0.00213	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—thyroid cancer	0.000581	0.00213	CcSEcCtD
Raloxifene—Hypoaesthesia—Epirubicin—thyroid cancer	0.000577	0.00212	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—thyroid cancer	0.000575	0.00211	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—thyroid cancer	0.000573	0.0021	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—thyroid cancer	0.000572	0.0021	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—thyroid cancer	0.000571	0.0021	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—thyroid cancer	0.00057	0.00209	CcSEcCtD
Raloxifene—ESR1—head—thyroid cancer	0.00057	0.0309	CbGeAlD
Raloxifene—Urethral disorder—Epirubicin—thyroid cancer	0.000568	0.00209	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—thyroid cancer	0.000561	0.00206	CcSEcCtD
Raloxifene—AOX1—lymph node—thyroid cancer	0.00056	0.0304	CbGeAlD
Raloxifene—Cardiac disorder—Epirubicin—thyroid cancer	0.000538	0.00198	CcSEcCtD
Raloxifene—Flushing—Epirubicin—thyroid cancer	0.000538	0.00198	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—thyroid cancer	0.000538	0.00197	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000534	0.00196	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—thyroid cancer	0.000532	0.00195	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00053	0.00194	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—thyroid cancer	0.000528	0.00194	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000527	0.00194	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—thyroid cancer	0.000526	0.00193	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—thyroid cancer	0.000526	0.00193	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—thyroid cancer	0.000498	0.00183	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—thyroid cancer	0.000498	0.00183	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—thyroid cancer	0.000497	0.00183	CcSEcCtD
Raloxifene—Angiopathy—Doxorubicin—thyroid cancer	0.000487	0.00179	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—thyroid cancer	0.000485	0.00178	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—thyroid cancer	0.00046	0.00169	CcSEcCtD
Raloxifene—CYP19A1—lymph node—thyroid cancer	0.000459	0.0249	CbGeAlD
Raloxifene—Vertigo—Epirubicin—thyroid cancer	0.000453	0.00166	CcSEcCtD
Raloxifene—Syncope—Epirubicin—thyroid cancer	0.000452	0.00166	CcSEcCtD
Raloxifene—SIGMAR1—lymph node—thyroid cancer	0.000451	0.0245	CbGeAlD
Raloxifene—HTR2B—lymph node—thyroid cancer	0.00045	0.0244	CbGeAlD
Raloxifene—Muscle spasms—Doxorubicin—thyroid cancer	0.000449	0.00165	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—thyroid cancer	0.000443	0.00163	CcSEcCtD
Raloxifene—Cough—Epirubicin—thyroid cancer	0.00044	0.00162	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—thyroid cancer	0.00043	0.00158	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—thyroid cancer	0.00043	0.00158	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—thyroid cancer	0.00043	0.00158	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000427	0.00157	CcSEcCtD
Raloxifene—CYP2B6—head—thyroid cancer	0.000421	0.0228	CbGeAlD
Raloxifene—Vertigo—Doxorubicin—thyroid cancer	0.000419	0.00154	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—thyroid cancer	0.000419	0.00154	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—thyroid cancer	0.00041	0.00151	CcSEcCtD
Raloxifene—Infection—Epirubicin—thyroid cancer	0.000409	0.0015	CcSEcCtD
Raloxifene—Cough—Doxorubicin—thyroid cancer	0.000407	0.0015	CcSEcCtD
Raloxifene—Shock—Epirubicin—thyroid cancer	0.000405	0.00149	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—thyroid cancer	0.000404	0.00148	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—thyroid cancer	0.000403	0.00148	CcSEcCtD
Raloxifene—Skin disorder—Epirubicin—thyroid cancer	0.0004	0.00147	CcSEcCtD
Raloxifene—ESR1—lymph node—thyroid cancer	0.000399	0.0216	CbGeAlD
Raloxifene—Hyperhidrosis—Epirubicin—thyroid cancer	0.000398	0.00146	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—thyroid cancer	0.000397	0.00146	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—thyroid cancer	0.000397	0.00146	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—thyroid cancer	0.000397	0.00146	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000395	0.00145	CcSEcCtD
Raloxifene—Infection—Doxorubicin—thyroid cancer	0.000379	0.00139	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000375	0.00138	CcSEcCtD
Raloxifene—Shock—Doxorubicin—thyroid cancer	0.000375	0.00138	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—thyroid cancer	0.000374	0.00137	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000373	0.00137	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—thyroid cancer	0.000372	0.00137	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—thyroid cancer	0.00037	0.00136	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000368	0.00135	CcSEcCtD
Raloxifene—Dyspepsia—Epirubicin—thyroid cancer	0.000362	0.00133	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000356	0.00131	CcSEcCtD
Raloxifene—Pain—Epirubicin—thyroid cancer	0.000352	0.00129	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000347	0.00127	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—thyroid cancer	0.000345	0.00127	CcSEcCtD
Raloxifene—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000337	0.00124	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—thyroid cancer	0.000335	0.00123	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000329	0.00121	CcSEcCtD
Raloxifene—Pain—Doxorubicin—thyroid cancer	0.000326	0.0012	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—thyroid cancer	0.000326	0.0012	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—thyroid cancer	0.000326	0.0012	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000312	0.00114	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—thyroid cancer	0.000301	0.00111	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—thyroid cancer	0.000301	0.00111	CcSEcCtD
Raloxifene—Diarrhoea—Epirubicin—thyroid cancer	0.000282	0.00103	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—thyroid cancer	0.000272	0.001	CcSEcCtD
Raloxifene—Vomiting—Epirubicin—thyroid cancer	0.000262	0.000961	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—thyroid cancer	0.000261	0.000957	CcSEcCtD
Raloxifene—Rash—Epirubicin—thyroid cancer	0.00026	0.000953	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—thyroid cancer	0.000259	0.000952	CcSEcCtD
Raloxifene—Headache—Epirubicin—thyroid cancer	0.000258	0.000947	CcSEcCtD
Raloxifene—Dizziness—Doxorubicin—thyroid cancer	0.000252	0.000925	CcSEcCtD
Raloxifene—ESR1—LKB1 signaling events—TP53—thyroid cancer	0.000247	0.00236	CbGpPWpGaD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.000246	0.00235	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000246	0.00234	CbGpPWpGaD
Raloxifene—Nausea—Epirubicin—thyroid cancer	0.000245	0.000898	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—thyroid cancer	0.000242	0.000889	CcSEcCtD
Raloxifene—ESR1—Leptin signaling pathway—CCND1—thyroid cancer	0.000241	0.0023	CbGpPWpGaD
Raloxifene—Rash—Doxorubicin—thyroid cancer	0.00024	0.000882	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—thyroid cancer	0.00024	0.000881	CcSEcCtD
Raloxifene—Headache—Doxorubicin—thyroid cancer	0.000239	0.000876	CcSEcCtD
Raloxifene—HTR6—GPCR ligand binding—PTCH1—thyroid cancer	0.000232	0.00221	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MINPP1—thyroid cancer	0.000227	0.00216	CbGpPWpGaD
Raloxifene—Nausea—Doxorubicin—thyroid cancer	0.000226	0.000831	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000226	0.00216	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000224	0.00214	CbGpPWpGaD
Raloxifene—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000224	0.00213	CbGpPWpGaD
Raloxifene—EBP—Metabolism—SLC5A5—thyroid cancer	0.000219	0.00209	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000218	0.00208	CbGpPWpGaD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.000217	0.00207	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—SST—thyroid cancer	0.000212	0.00202	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—PTCH1—thyroid cancer	0.000211	0.00202	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.00021	0.00201	CbGpPWpGaD
Raloxifene—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000209	0.00199	CbGpPWpGaD
Raloxifene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000208	0.00198	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000205	0.00196	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CALCA—thyroid cancer	0.000204	0.00194	CbGpPWpGaD
Raloxifene—CYP2B6—Biological oxidations—RXRA—thyroid cancer	0.000198	0.00189	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—TRIM33—thyroid cancer	0.000198	0.00189	CbGpPWpGaD
Raloxifene—AOX1—Disease—TPR—thyroid cancer	0.000194	0.00185	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—SST—thyroid cancer	0.000193	0.00184	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NDUFA13—thyroid cancer	0.000193	0.00184	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—TPR—thyroid cancer	0.000191	0.00183	CbGpPWpGaD
Raloxifene—AOX1—Disease—PRKAR1A—thyroid cancer	0.000191	0.00182	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000189	0.0018	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000188	0.0018	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CALCA—thyroid cancer	0.000186	0.00178	CbGpPWpGaD
Raloxifene—EBP—Metabolism—RXRA—thyroid cancer	0.000184	0.00176	CbGpPWpGaD
Raloxifene—AOX1—Disease—MEN1—thyroid cancer	0.000182	0.00174	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CHST14—thyroid cancer	0.000181	0.00173	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MEN1—thyroid cancer	0.00018	0.00172	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000179	0.00171	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CALCB—thyroid cancer	0.000178	0.0017	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000178	0.0017	CbGpPWpGaD
Raloxifene—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000169	0.00162	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TRIM33—thyroid cancer	0.000169	0.00161	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000168	0.0016	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—TP53—thyroid cancer	0.000168	0.0016	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000167	0.0016	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CALCB—thyroid cancer	0.000163	0.00155	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—TPR—thyroid cancer	0.000162	0.00155	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PRKAR1A—thyroid cancer	0.00016	0.00152	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—PPARG—thyroid cancer	0.000158	0.00151	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TRIM33—thyroid cancer	0.000154	0.00147	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—TSHR—thyroid cancer	0.000154	0.00147	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000154	0.00147	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—HRAS—thyroid cancer	0.000152	0.00145	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000149	0.00142	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000148	0.00141	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—HPGD—thyroid cancer	0.000146	0.00139	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MINPP1—thyroid cancer	0.000146	0.00139	CbGpPWpGaD
Raloxifene—AOX1—Disease—CALCA—thyroid cancer	0.000145	0.00138	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—AKT1—thyroid cancer	0.000145	0.00138	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—THRB—thyroid cancer	0.000143	0.00136	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—TSHR—thyroid cancer	0.00014	0.00134	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—TSHR—thyroid cancer	0.00014	0.00133	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000138	0.00131	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000137	0.00131	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CALCB—thyroid cancer	0.000136	0.00129	CbGpPWpGaD
Raloxifene—ESR1—Leptin signaling pathway—AKT1—thyroid cancer	0.000134	0.00128	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000133	0.00127	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—PTEN—thyroid cancer	0.000132	0.00126	CbGpPWpGaD
Raloxifene—AOX1—Disease—CDK1—thyroid cancer	0.000131	0.00125	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TRIM33—thyroid cancer	0.000129	0.00123	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—TSHR—thyroid cancer	0.000128	0.00122	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—RXRA—thyroid cancer	0.000126	0.0012	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000126	0.0012	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000126	0.0012	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000126	0.0012	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000126	0.0012	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NDUFA13—thyroid cancer	0.000124	0.00118	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.000123	0.00118	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—SLC5A5—thyroid cancer	0.000121	0.00116	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—RXRA—thyroid cancer	0.00012	0.00115	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—SST—thyroid cancer	0.00012	0.00114	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PTCH1—thyroid cancer	0.000119	0.00113	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000118	0.00113	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—NRAS—thyroid cancer	0.000118	0.00112	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CHST14—thyroid cancer	0.000116	0.00111	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PPARG—thyroid cancer	0.000116	0.00111	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CALCA—thyroid cancer	0.000115	0.0011	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000114	0.00109	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000114	0.00109	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TCF7L1—thyroid cancer	0.000113	0.00108	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.00011	0.00105	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—SST—thyroid cancer	0.000109	0.00104	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—SST—thyroid cancer	0.000109	0.00104	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PTCH1—thyroid cancer	0.000108	0.00103	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000107	0.00102	CbGpPWpGaD
Raloxifene—AOX1—Disease—NRG1—thyroid cancer	0.000105	0.001	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CALCA—thyroid cancer	0.000105	0.001	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000105	0.000999	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CALCA—thyroid cancer	0.000105	0.000998	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TCF7L1—thyroid cancer	0.000103	0.000982	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—RXRA—thyroid cancer	0.000102	0.000973	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000102	0.000972	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—KRAS—thyroid cancer	0.000101	0.000967	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000101	0.000965	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—SST—thyroid cancer	9.92e-05	0.000946	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CHST14—thyroid cancer	9.85e-05	0.000939	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—TPR—thyroid cancer	9.66e-05	0.000921	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CALCA—thyroid cancer	9.55e-05	0.000911	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CDK1—thyroid cancer	9.47e-05	0.000903	CbGpPWpGaD
Raloxifene—AOX1—Disease—TERT—thyroid cancer	9.46e-05	0.000902	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—HPGD—thyroid cancer	9.38e-05	0.000894	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	9.22e-05	0.00088	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTGS2—thyroid cancer	9.14e-05	0.000872	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MEN1—thyroid cancer	9.08e-05	0.000866	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	9.06e-05	0.000864	CbGpPWpGaD
Raloxifene—AOX1—Disease—HIF1A—thyroid cancer	9.04e-05	0.000863	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—RXRA—thyroid cancer	9e-05	0.000859	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CDK1—thyroid cancer	8.64e-05	0.000825	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—HRAS—thyroid cancer	8.62e-05	0.000822	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TCF7L1—thyroid cancer	8.58e-05	0.000818	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	8.54e-05	0.000815	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.45e-05	0.000806	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TPR—thyroid cancer	8.39e-05	0.0008	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TSHR—thyroid cancer	8.26e-05	0.000788	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PRKAR1A—thyroid cancer	8.25e-05	0.000787	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PRKAR1A—thyroid cancer	8.12e-05	0.000775	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTEN—thyroid cancer	7.97e-05	0.000761	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—PPARG—thyroid cancer	7.96e-05	0.00076	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—HPGD—thyroid cancer	7.94e-05	0.000757	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	7.84e-05	0.000748	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MEN1—thyroid cancer	7.76e-05	0.00074	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	7.65e-05	0.00073	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—AKT1—thyroid cancer	7.61e-05	0.000726	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—PPARG—thyroid cancer	7.6e-05	0.000725	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TSHR—thyroid cancer	7.54e-05	0.000719	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.51e-05	0.000716	CbGpPWpGaD
Raloxifene—AOX1—Disease—BRAF—thyroid cancer	7.49e-05	0.000714	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.48e-05	0.000713	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PRKAR1A—thyroid cancer	7.41e-05	0.000707	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MEN1—thyroid cancer	7.09e-05	0.000676	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTCH1—thyroid cancer	7.02e-05	0.00067	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MINPP1—thyroid cancer	6.61e-05	0.000631	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PPARG—thyroid cancer	6.44e-05	0.000614	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.44e-05	0.000614	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SST—thyroid cancer	6.42e-05	0.000612	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTCH1—thyroid cancer	6.41e-05	0.000611	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.34e-05	0.000605	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SLC5A5—thyroid cancer	6.28e-05	0.000599	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TSHR—thyroid cancer	6.28e-05	0.000599	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CALCA—thyroid cancer	6.18e-05	0.00059	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PRKAR1A—thyroid cancer	6.18e-05	0.000589	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—RXRA—thyroid cancer	6.07e-05	0.000579	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—thyroid cancer	6.05e-05	0.000577	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MEN1—thyroid cancer	5.9e-05	0.000563	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.88e-05	0.000561	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SST—thyroid cancer	5.86e-05	0.000559	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CALCA—thyroid cancer	5.64e-05	0.000538	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NDUFA13—thyroid cancer	5.62e-05	0.000536	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CDK1—thyroid cancer	5.59e-05	0.000534	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TPR—thyroid cancer	5.39e-05	0.000514	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTCH1—thyroid cancer	5.34e-05	0.000509	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	5.3e-05	0.000505	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CHST14—thyroid cancer	5.29e-05	0.000504	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTEN—thyroid cancer	5.28e-05	0.000503	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—RXRA—thyroid cancer	5.27e-05	0.000503	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.13e-05	0.000489	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CDK1—thyroid cancer	5.11e-05	0.000487	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—thyroid cancer	5.07e-05	0.000483	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SST—thyroid cancer	4.88e-05	0.000466	CbGpPWpGaD
Raloxifene—AOX1—Disease—NRAS—thyroid cancer	4.71e-05	0.000449	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CALCA—thyroid cancer	4.7e-05	0.000448	CbGpPWpGaD
Raloxifene—EBP—Metabolism—AKT1—thyroid cancer	4.59e-05	0.000438	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TPR—thyroid cancer	4.56e-05	0.000435	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRG1—thyroid cancer	4.49e-05	0.000428	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	4.49e-05	0.000428	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTEN—thyroid cancer	4.42e-05	0.000421	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—HPGD—thyroid cancer	4.26e-05	0.000406	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CDK1—thyroid cancer	4.25e-05	0.000406	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRG1—thyroid cancer	4.1e-05	0.000391	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.07e-05	0.000388	CbGpPWpGaD
Raloxifene—AOX1—Disease—KRAS—thyroid cancer	4.05e-05	0.000386	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TERT—thyroid cancer	4.03e-05	0.000385	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SLC5A5—thyroid cancer	4.03e-05	0.000385	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HIF1A—thyroid cancer	3.86e-05	0.000368	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—PPARG—thyroid cancer	3.83e-05	0.000366	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TERT—thyroid cancer	3.68e-05	0.000351	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HIF1A—thyroid cancer	3.52e-05	0.000336	CbGpPWpGaD
Raloxifene—AOX1—Disease—HRAS—thyroid cancer	3.44e-05	0.000328	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRG1—thyroid cancer	3.41e-05	0.000326	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SLC5A5—thyroid cancer	3.41e-05	0.000326	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—NRAS—thyroid cancer	3.4e-05	0.000324	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—RXRA—thyroid cancer	3.39e-05	0.000323	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PPARG—thyroid cancer	3.33e-05	0.000318	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.2e-05	0.000305	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—BRAF—thyroid cancer	3.19e-05	0.000305	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—NRAS—thyroid cancer	3.1e-05	0.000296	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TERT—thyroid cancer	3.07e-05	0.000292	CbGpPWpGaD
Raloxifene—AOX1—Disease—AKT1—thyroid cancer	3.04e-05	0.00029	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—AKT1—thyroid cancer	3.01e-05	0.000287	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HIF1A—thyroid cancer	2.93e-05	0.00028	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—KRAS—thyroid cancer	2.92e-05	0.000279	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BRAF—thyroid cancer	2.91e-05	0.000278	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—RXRA—thyroid cancer	2.87e-05	0.000274	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.79e-05	0.000266	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—KRAS—thyroid cancer	2.67e-05	0.000255	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—thyroid cancer	2.62e-05	0.00025	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—AKT1—thyroid cancer	2.55e-05	0.000243	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—HRAS—thyroid cancer	2.49e-05	0.000237	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TPR—thyroid cancer	2.45e-05	0.000233	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BRAF—thyroid cancer	2.43e-05	0.000232	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.42e-05	0.00023	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.41e-05	0.00023	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.33e-05	0.000222	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTEN—thyroid cancer	2.28e-05	0.000218	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	2.27e-05	0.000216	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.25e-05	0.000215	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	2.21e-05	0.00021	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.19e-05	0.000209	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PPARG—thyroid cancer	2.14e-05	0.000204	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CCND1—thyroid cancer	2.13e-05	0.000203	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTEN—thyroid cancer	2.05e-05	0.000196	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—NRAS—thyroid cancer	2.01e-05	0.000191	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	2e-05	0.000191	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.83e-05	0.000175	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—NRAS—thyroid cancer	1.83e-05	0.000175	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PPARG—thyroid cancer	1.81e-05	0.000173	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CCND1—thyroid cancer	1.77e-05	0.000169	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.73e-05	0.000165	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTEN—thyroid cancer	1.71e-05	0.000163	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—thyroid cancer	1.68e-05	0.00016	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KRAS—thyroid cancer	1.58e-05	0.00015	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—RXRA—thyroid cancer	1.54e-05	0.000147	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—thyroid cancer	1.54e-05	0.000146	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—NRAS—thyroid cancer	1.53e-05	0.000146	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—AKT1—thyroid cancer	1.52e-05	0.000145	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.47e-05	0.00014	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTEN—thyroid cancer	1.47e-05	0.00014	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.42e-05	0.000136	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—thyroid cancer	1.4e-05	0.000134	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—HRAS—thyroid cancer	1.34e-05	0.000128	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—AKT1—thyroid cancer	1.32e-05	0.000126	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KRAS—thyroid cancer	1.31e-05	0.000125	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.3e-05	0.000124	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTEN—thyroid cancer	1.24e-05	0.000118	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—AKT1—thyroid cancer	1.18e-05	0.000113	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—thyroid cancer	1.17e-05	0.000111	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—HRAS—thyroid cancer	1.12e-05	0.000106	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—AKT1—thyroid cancer	9.86e-06	9.4e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PPARG—thyroid cancer	9.72e-06	9.27e-05	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—AKT1—thyroid cancer	8.46e-06	8.07e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—thyroid cancer	7.65e-06	7.29e-05	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—AKT1—thyroid cancer	7.16e-06	6.83e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTEN—thyroid cancer	6.67e-06	6.36e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—AKT1—thyroid cancer	3.84e-06	3.67e-05	CbGpPWpGaD
